794 related articles for article (PubMed ID: 25932675)
1. Targeting cancer with kinase inhibitors.
Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
[TBL] [Abstract][Full Text] [Related]
2. The Stress Kinase p38α as a Target for Cancer Therapy.
Igea A; Nebreda AR
Cancer Res; 2015 Oct; 75(19):3997-4002. PubMed ID: 26377941
[TBL] [Abstract][Full Text] [Related]
3. [The HER3/ERBB3 receptor: the dark side of the ERBB planet].
Larbouret C; Gaborit N; Poul MA; Pèlegrin A; Chardès T
Med Sci (Paris); 2015 May; 31(5):465-8. PubMed ID: 26059291
[No Abstract] [Full Text] [Related]
4. Targeting cancer with small molecule kinase inhibitors.
Zhang J; Yang PL; Gray NS
Nat Rev Cancer; 2009 Jan; 9(1):28-39. PubMed ID: 19104514
[TBL] [Abstract][Full Text] [Related]
5. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
6. Enzastaurin.
Chen YB; LaCasce AS
Expert Opin Investig Drugs; 2008 Jun; 17(6):939-44. PubMed ID: 18491994
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies.
Lee JT; McCubrey JA
Expert Opin Ther Targets; 2002 Dec; 6(6):659-78. PubMed ID: 12472379
[TBL] [Abstract][Full Text] [Related]
8. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
9. Protein kinases: From targets to anti-cancer drugs.
Cruzalegui F
Ann Pharm Fr; 2010 Jul; 68(4):254-9. PubMed ID: 20637357
[TBL] [Abstract][Full Text] [Related]
10. BRAF inhibitors in cancer therapy.
Hertzman Johansson C; Egyhazi Brage S
Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
[TBL] [Abstract][Full Text] [Related]
11. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
12. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
13. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
14. Kinase Inhibitor Screening in Myeloid Malignancies.
Tyner JW
Hematol Oncol Clin North Am; 2017 Aug; 31(4):693-704. PubMed ID: 28673396
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
Bixby D; Talpaz M
Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.
Miller MA; Sullivan RJ; Lauffenburger DA
Clin Cancer Res; 2017 Feb; 23(3):623-629. PubMed ID: 27895032
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinases as therapeutic targets in melanoma.
Miller DM; Flaherty KT
Pigment Cell Melanoma Res; 2014 May; 27(3):351-65. PubMed ID: 24405945
[TBL] [Abstract][Full Text] [Related]
19. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
20. Druggable signaling proteins.
Sioud M; Leirdal M
Methods Mol Biol; 2007; 361():1-24. PubMed ID: 17172705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
